-- 四川バイオキン製薬（上海証券取引所：688506）の第1四半期決算は、前年同期の5億3140万元から7億7460万元へと純損失が拡大した。 同社が火曜日に上海証券取引所に提出した書類によると、1株当たり損失も1.33元から1.88元へと拡大した。 一方、売上高は6740万元から9460万元へと40%増加した。バイオキンは、これは同社製品に対する市場需要の増加によるものだと説明している。 同社の株価は直近の取引で約3%下落した。
Related Articles
Asia
Nomura Adjusts Axis Bank's Price Target to INR1,560 from INR1,500, Keeps at Buy
$BOM:532215$NSE:AXISBANK
Equities
NMDC Energy Posts Lower Preliminary Q1 Profit; Contract Revenue Up
NMDC Energy (ADX:NMDCENR) said Tuesday its preliminary profit for the first quarter tumbled, while contract revenue increased year over year.Preliminary profit attributable to shareholders for the three months ended March 31 was 79.6 million Emirati dirhams, compared with 216.2 million dirhams earlier. EPS moved to 0.016 dirham from 0.043 dirham.The offshore and onshore energy sector engineering and construction company's contract revenue was 4.96 billion dirhams, compared with 3.73 billion dirhams a year ago.
$ADX:NMDCENR
Asia
Nickel Industries Executes $450 Million Syndicated Loan Facilities Led by BNI
Nickel Industries (ASX:NIC) said it has executed new $450 million syndicated loan facilities led by PT Bank Negara Indonesia (BNI), comprising a $350 million term loan and a $100 million revolving loan facility, both unsecured, according to a Tuesday Australian bourse filing.The company said the facilities have been established to retire its existing $398 million of bank loans outstanding as of March 31, as well as for general working capital purposes.The interest rate will be a margin above the Secured Overnight Financing Rate (SOFR), currently about 3.66%, at 3.50% for the first six months and thereafter linked to the company's leverage level, the filing added.Following the refinancing, the company will have net debt of about $994 million, comprising $800 million of senior unsecured notes expiring October 2030, the $350 million term loan, and $100 million revolver, and $256 million in cash, it added.
$ASX:NIC